Cardiovascular health, heart failure, atherosclerosis, and cardiac research
417 articoli
A landmark 8,500-patient trial challenges 40 years of cardiology practice, finding beta blockers unnecessary after uncomplicated heart attacks.
A landmark Phase 3 trial evaluates whether omecamtiv mecarbil, a cardiac myosin activator, reduces cardiovascular death in HFrEF patients.
A phase 3 trial adding ERN/LRPT to statin therapy for dyslipidemia was terminated early, raising questions about the drug's clinical future.
A newly discovered protein called HELZ2 controls how much harmful cholesterol the liver releases, opening a fresh path to heart disease treatment.
A Phase 1 trial examines if the triple-agonist GLP-1 drug retatrutide changes how the body processes the beta-blocker metoprolol.
A new NEJM perspective examines hypertension's central role in cardiovascular risk, with implications for prevention and clinical management.
A landmark Lancet registry finds coronary microvascular dysfunction raises major cardiac event risk by 91%, even after treating visible blockages.
A Lancet review spotlights how small vessel dysfunction silently worsens atherosclerotic coronary disease, reshaping diagnosis and treatment.
Simon Hill's cardiovascular masterclass covers the Portfolio Diet, plaque regression, ApoB testing, and the sodium-potassium ratio with top experts.
A million-man study finds that adolescent cardiorespiratory fitness delivers net cardiovascular benefits that far outweigh any AF risk.
A muscle enzyme that declines in heart attack patients may hold the key to preserving cardiac function after MI.
A 2-year clinical trial testing Juice Plus+ products against low-grade inflammation and biological aging markers in overweight seniors was terminated before completion.
